Stimulating Research and Development of New Antibiotics While Ensuring Sustainable Use and Access: Further Insights from the DRIVE-AB Project and Others

Esther Bettiol; Judith Hackett; Stephan Harbarth

doi:10.1177/1073110518782910

Stimulating Research and Development of New Antibiotics While Ensuring Sustainable Use and Access: Further Insights from the DRIVE-AB Project and Others

J Law Med Ethics. 2018 Jun;46(1_suppl):5-8. doi: 10.1177/1073110518782910.

Authors

Esther Bettiol¹, Judith Hackett¹, Stephan Harbarth¹

Affiliation

¹ Esther Bettiol, M.D., Ph.D., is Scientific Officer for the DRIVE-AB project at the University of Geneva, Geneva, Switzerland. She has an M.D. and a Ph.D. from the University of Geneva. Judith Hackett, M.B.A., is Global Director, Pricing and Reimbursement INFECTION at AstraZeneca in Gaithersburg, MD. She has a B.S.C. P.H.M. degree from the University of Toronto (Canada), an M.B.A. from the Schulich School of Business (York University, Toronto), and a Diploma in Health Economics from the University of Toronto. Stephan Harbarth, M.D., M.S., is an Associate Professor and Senior Consultant, Attending in Geriatric and General Infectious Diseases, and Associate Hospital Epidemiologist at the Geneva University Hospitals and Faculty of Medicine in Geneva, Switzerland.

PMID: 30146955
DOI: 10.1177/1073110518782910

Abstract

Global discussions are ongoing on how to stimulate antibiotic research and development in order to provide patients with new antibiotics able to address the challenges of antimicrobial resistance. In this supplement, we present nine articles derived from the research performed as part of the Innovative Medicine Initiative-funded DRIVE-AB project and others. These publications provide new evidence and arguments in the debate around economic incentives to stimulate antibiotic innovation, including characteristics, implementation and governance.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents*
Biomedical Research*
Drug Discovery*
Drug Resistance, Microbial
Humans
Motivation
Public-Private Sector Partnerships*

Substances

Anti-Bacterial Agents